Trial Profile
A Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of Telatinib, a Selective Inhibitor of the Vascular Endothelial Growth Factor (VEGF) Receptor, in Adult Chinese Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Telatinib (Primary)
- Indications Colorectal cancer; Head and neck cancer; Malignant melanoma; Oesophageal cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors EOC Pharma
- 04 Jun 2019 Safety and tolerability results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 09 May 2019 Status changed from recruiting to completed.
- 28 Nov 2017 Status changed from not yet recruiting to recruiting.